FDA approves Amgen’s T cell engager in aggressive form of lung cancer
The FDA on Thursday granted accelerated approval to Amgen’s bispecific T cell engager tarlatamab in small cell lung cancer, an aggressive …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
